Osivax
French tech company | Builders Republic
About
Clinical-stage biotech developing universal vaccines that target the parts of viruses common to all strains — its oligoDOM technology trains long-lasting T-cell immunity alongside antibodies, with lead programs aiming for a single shot protecting against all flu strains and coronavirus variants.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series B
- Founded
- 2017
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 10 M€ raised since 2020
Funding rounds
- Series B — 2025
Investors
- Family Offices
- Meiji Seika Pharma